web analytics

Preliminary results of Enzymatica’s placebo-controlled, randomized study did not meet the primary end-point

Preliminary results show that Enzymatica’s prospective, randomized, double-blinded multicenter study did not meet the primary end-point “Significant improvement of quality of life during treatment with ColdZyme compared to placebo in common cold”.
Totally 700 participants were enrolled at ten study centers in Germany. The more than 400 participants who caught a cold were randomized to treatment with either ColdZyme or placebo in a double-blind fashion.  

The primary objective was to prove that ColdZyme improved quality of life during a common cold period, compared to placebo, assessed by

Source: Preliminary results of Enzymatica’s placebo-controlled, randomized study did not meet the primary end-point

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.